ICU Medical Inc
ICUIICU Medical Inc (ICUI) is a healthcare company specializing in the development, manufacturing, and sale of medical devices and systems used in infusion therapy, including intravenous (IV) solutions, administration sets, and related accessories. The company focuses on enhancing patient safety and outcomes through innovative products designed for hospitals, clinics, and other medical settings. Founded in 1984 and headquartered in Illinois, ICU Medical has established a reputation for its commitment to quality and clinical safety advancements in the medical device industry.
Company News
ICU Medical's General Counsel Ruth Sanzone sold 2,447 shares worth ~$304,000 in an open-market transaction. While the Smiths Medical integration nears completion with manufacturing consolidation largely finished, the company faces headwinds from ~$1 billion in net debt, tariff pressures of $40-50 million annually, and a stock down 16% over the pa...
The Iran-Israel conflict and potential Strait of Hormuz disruption are creating supply chain pressures on medical supplies through petrochemical derivatives. Key inputs like naphtha and methanol used in pharmaceutical packaging and drug synthesis are experiencing price increases. While hospitals haven't yet felt the impact, analysts expect cost p...
The global IV solutions market is projected to grow from USD 13.35 billion in 2025 to USD 29.47 billion by 2035, with a CAGR of 8.24%. Growth is driven by increasing prevalence of chronic diseases, rising hospital admissions, and growing demand for parenteral nutrition and critical care solutions. The U.S. market alone is expected to reach USD 8....
The global intravenous infusion pump market was valued at USD 6.72 billion in 2025 and is projected to reach USD 14.02 billion by 2035, growing at a CAGR of 7.6%. Growth is driven by increasing chronic diseases, aging populations, technological advancements in smart pumps, and rising demand for precise medication delivery in hospitals and home ca...
ICU Medical reported Q2 2025 earnings with a significant EPS beat of $2.10, exceeding analyst expectations by 40%. Despite strong profitability, the company faces challenges from regulatory issues, tariffs, and segment performance variability, leading to cautious FY2025 guidance.
